Search Results - "Wullimann, David"
-
1
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Published in EBioMedicine (01-12-2021)“…Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective…”
Get full text
Journal Article -
2
-
3
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
Published in Molecular medicine (Cambridge, Mass.) (13-05-2022)“…Mucosa-associated invariant T (MAIT) cells are unconventional T cells with innate-like capacity to rapidly respond to microbial infection via MR1-restricted…”
Get full text
Journal Article -
4
-
5
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Published in Cell (01-10-2020)“…SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. Here, we systematically mapped the functional…”
Get full text
Journal Article -
6
Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity
Published in Proceedings of the National Academy of Sciences - PNAS (09-02-2021)“…Dendritic cells (DCs) and monocytes are crucial mediators of innate and adaptive immune responses during viral infection, but misdirected responses by these…”
Get full text
Journal Article -
7
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Published in Immunity (Cambridge, Mass.) (13-09-2022)“…Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2 mRNA vaccination. Here, we assessed the single-cell profile of…”
Get full text
Journal Article -
8
MAIT cell activation and dynamics associated with COVID-19 disease severity
Published in Science immunology (28-09-2020)“…Severe COVID-19 is characterized by excessive inflammation of the lower airways. The balance of protective versus pathological immune responses in COVID-19 is…”
Get more information
Journal Article -
9
Functional SARS-CoV-2 cross-reactive CD4 + T cells established in early childhood decline with age
Published in Proceedings of the National Academy of Sciences - PNAS (21-03-2023)“…Pre-existing SARS-CoV-2-reactive T cells have been identified in SARS-CoV-2-unexposed individuals, potentially modulating COVID-19 and vaccination outcomes…”
Get full text
Journal Article -
10
Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency
Published in Journal of clinical immunology (01-05-2022)“…Purpose Limited data is available on the effect of COVID-19 vaccination in immunocompromised individuals. Here, we provide the results from vaccinating a…”
Get full text
Journal Article -
11
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
Published in Blood (01-12-2022)Get full text
Journal Article -
12
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Published in Molecular medicine (Cambridge, Mass.) (08-02-2022)“…Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the…”
Get full text
Journal Article -
13
The HLA-B –21 M/T dimorphism associates with disease severity in COVID-19
Published in Genes and immunity (01-11-2024)“…Abstract Host genetics shape immune responses and influence severity of infectious diseases. The HLA-B –21 M/T dimorphism tunes the functionality of natural…”
Get full text
Journal Article -
14
Elevated CD21 low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency
Published in Journal of clinical immunology (01-05-2022)“…Limited data is available on the effect of COVID-19 vaccination in immunocompromised individuals. Here, we provide the results from vaccinating a single-center…”
Get full text
Journal Article -
15
The Karolinska KI/K COVID‐19 immune atlas: An open resource for immunological research and educational purposes
Published in Scandinavian journal of immunology (01-07-2022)“…The Karolinska KI/K COVID‐19 Immune Atlas project was conceptualized in March 2020 as a part of the academic research response to the developing SARS‐CoV‐2…”
Get full text
Journal Article -
16
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDResearch in context
Published in EBioMedicine (01-11-2024)“…Background: Immunocompromised patients with primary and secondary immunodeficiencies have shown impaired responses to SARS-CoV-2 mRNA vaccines, necessitating…”
Get full text
Journal Article -
17
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDResearch in context
Published in EBioMedicine (01-08-2023)“…Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective…”
Get full text
Journal Article -
18
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID
Published in EBioMedicine (01-11-2024)“…Immunocompromised patients with primary and secondary immunodeficiencies have shown impaired responses to SARS-CoV-2 mRNA vaccines, necessitating…”
Get full text
Journal Article -
19
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Published in EBioMedicine (01-08-2023)“…Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical…”
Get full text
Journal Article -
20
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Published in Journal of hematology (01-08-2023)“…Background: Patients with chronic lymphocytic leukemia (CLL) are vulnerable to coronavirus disease 2019 (COVID-19) and are at risk of inferior response to…”
Get full text
Journal Article